Fmr LLC Has $73.49 Million Stake in Perspective Therapeutics, Inc. (NYSE:CATX)

Fmr LLC raised its holdings in Perspective Therapeutics, Inc. (NYSE:CATX) by 3,994.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 5,504,822 shares of the company’s stock after buying an additional 5,370,392 shares during the period. Fmr LLC owned 8.16% of Perspective Therapeutics worth $73,489,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in CATX. The Manufacturers Life Insurance Company increased its position in shares of Perspective Therapeutics by 8.9% in the third quarter. The Manufacturers Life Insurance Company now owns 20,514 shares of the company’s stock valued at $274,000 after acquiring an additional 1,672 shares during the last quarter. Sykon Capital LLC increased its position in shares of Perspective Therapeutics by 4.7% during the 2nd quarter. Sykon Capital LLC now owns 37,932 shares of the company’s stock worth $378,000 after purchasing an additional 1,717 shares during the last quarter. US Bancorp DE raised its stake in shares of Perspective Therapeutics by 142.7% during the 3rd quarter. US Bancorp DE now owns 6,576 shares of the company’s stock worth $88,000 after purchasing an additional 3,866 shares in the last quarter. nVerses Capital LLC acquired a new stake in shares of Perspective Therapeutics in the 3rd quarter valued at approximately $57,000. Finally, Intech Investment Management LLC acquired a new stake in shares of Perspective Therapeutics in the 3rd quarter valued at approximately $137,000. 54.66% of the stock is owned by institutional investors.

Insider Activity at Perspective Therapeutics

In related news, CEO Johan M. Spoor purchased 8,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 4th. The stock was acquired at an average price of $3.77 per share, with a total value of $30,160.00. Following the completion of the purchase, the chief executive officer now directly owns 36,257 shares in the company, valued at $136,688.89. This trade represents a 28.31 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Jonathan Robert Hunt acquired 12,829 shares of Perspective Therapeutics stock in a transaction on Monday, November 25th. The shares were purchased at an average price of $3.82 per share, for a total transaction of $49,006.78. Following the completion of the purchase, the chief financial officer now directly owns 48,800 shares of the company’s stock, valued at approximately $186,416. This represents a 35.66 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 41,595 shares of company stock worth $156,785. Corporate insiders own 3.52% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on CATX. UBS Group started coverage on shares of Perspective Therapeutics in a report on Thursday, October 24th. They set a “buy” rating and a $20.00 target price on the stock. Wedbush reaffirmed an “outperform” rating and issued a $11.00 target price (down from $20.00) on shares of Perspective Therapeutics in a report on Thursday, November 21st. Royal Bank of Canada reduced their price target on Perspective Therapeutics from $25.00 to $16.00 and set an “outperform” rating for the company in a report on Monday, November 25th. Bank of America lowered Perspective Therapeutics from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $24.00 to $5.00 in a research note on Monday, November 25th. Finally, Truist Financial assumed coverage on Perspective Therapeutics in a research report on Wednesday, September 25th. They issued a “buy” rating and a $21.00 price objective for the company. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $15.14.

Perspective Therapeutics Stock Up 0.3 %

Perspective Therapeutics stock opened at $3.72 on Friday. Perspective Therapeutics, Inc. has a 12 month low of $2.28 and a 12 month high of $19.05. The stock’s 50 day moving average is $9.93 and its 200-day moving average is $12.00.

Perspective Therapeutics (NYSE:CATX) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.21). Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%. The business had revenue of $0.37 million during the quarter. Research analysts predict that Perspective Therapeutics, Inc. will post -0.88 earnings per share for the current fiscal year.

Perspective Therapeutics Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.